This tag is associated with 1 post

Relovair, the Salford Lung Study, and the First “Real World” Trial Before Approval: A Breath of Fresh Air for Payers?

Earlier this month, GlaxoSmithKline (GSK) and a number of collaborators announced an innovative new study pertaining to Relovair, the company’s once-a-day combination of corticosteroid (fluticasone furoate) and long-acting beta agonist (vilanterol trifenatate), under development for the treatment of asthma and chronic obstructive pulmonary disorder (COPD). The year-long Salford Lung Study, anticipated to enrol around 4,000 … Continue reading

Enter your email address to follow this blog and receive notifications of new posts by email.

Download extract from IHS Flexible Pricing strategies multi client study
Drug Price Erosion Multi Client Study extract download

About This Blog

In this blog, our experts share regular insights on the global life sciences industry. Join us as we look at issues in healthcare policy, market access, pricing and reimbursement and R&D. Comments are welcome!
40 countries covered. Download a sample chapter on Brazil
Download a complimentary white paper on market-access risk ratings
Download a sample of the primary research and analysis on French P&R reform

Follow IHS Life Sciences on Twitter


Get every new post delivered to your Inbox.

Join 346 other followers